Medtronic backs antisense-coated stent with early data
This article was originally published in Clinica
Executive Summary
Medtronic's stent coated with AVI BioPharma's NeuGene antisense compound, Resten-NG, has produced promising results in a preclinical study. Data showed that the drug-coated device can not only significantly reduce coronary restenosis, but it may also allow arteries to heal faster than other compounds currently being assessed on stents, claimed AVI, of Portland, Oregon.